Recombinant
RabMAb

Recombinant Anti-IL-27-A antibody [EPR18247-101] (ab190831)

Overview

  • Product name

    Anti-IL-27-A antibody [EPR18247-101]
    See all IL-27-A primary antibodies
  • Description

    Rabbit monoclonal [EPR18247-101] to IL-27-A
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IPmore details
    Unsuitable for: Flow Cyt,ICC/IF or IHC-P
  • Species reactivity

    Reacts with: Mouse
  • Immunogen

    Recombinant fragment within Mouse IL-27-A aa 1 to the C-terminus. The exact sequence is proprietary.
    Database link: Q8K3I6

  • Positive control

    • WB: RAW 264.7 (treated with 100ng/ml LPS for 6h) whole cell lysate. IP: RAW 264.7 (treated with 1µg/ml LPS for 6h) whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer

    Preservative: 0.01% Sodium azide
    Constituents: PBS, 40% Glycerol, 0.05% BSA
  • Concentration information loading...
  • Purity

    Protein A purified
  • Clonality

    Monoclonal
  • Clone number

    EPR18247-101
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab190831 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 27 kDa (predicted molecular weight: 27 kDa).
IP 1/30.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF or IHC-P.
  • Target

    • Function

      Cytokine with pro- and anti-inflammatory properties, that can regulate T helper cell development, suppress T-cell proliferation, stimulate cytotoxic T cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL-27 subunit p28 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replivation.
    • Tissue specificity

      Expressed in monocytes and in placenta.
    • Sequence similarities

      Belongs to the IL-6 superfamily.
    • Post-translational
      modifications

      O-glycosylated.
    • Cellular localization

      Secreted. Does not seem to be secreted without coexpression of EBI3.
    • Information by UniProt
    • Database links

    • Alternative names

      • EBI3 antibody
      • IL 27 antibody
      • IL 27 p28 subunit antibody
      • IL 27A antibody
      • IL 30 antibody
      • IL-27 subunit alpha antibody
      • IL-27-A antibody
      • IL27 antibody
      • IL27-A antibody
      • IL27A antibody
      • IL27A_HUMAN antibody
      • IL27p28 antibody
      • IL30 antibody
      • Interleukin 27 antibody
      • Interleukin 27 subunit alpha antibody
      • Interleukin 27, 28-KD subunit antibody
      • Interleukin 30 antibody
      • Interleukin-27 subunit alpha antibody
      • p28 antibody
      see all

    Images

    • All lanes : Anti-IL-27-A antibody [EPR18247-101] (ab190831) at 1/1000 dilution

      Lane 1 : Untreated RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
      Lane 2 : RAW 264.7 (treated with 100ng/ml LPS for 6h) whole cell lysate

      Lysates/proteins at 20 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Developed using the ECL technique.

      Predicted band size: 27 kDa
      Observed band size: 27 kDa


      Exposure time: 3 minutes


      Blocking and dilution buffer: 5% NFDM/TBST.

      The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 19620301, PMID: 12121660).

      This blot was developed using a higher sensitivity ECL substrate.

       

    • IL-27-A was immunoprecipitated from 0.35 mg of RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) (treated with 1μg/ml LPS for 6h) whole cell lysate with ab190831 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab190831 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.

      Lane 1: RAW 264.7 (treated with 1μg/ml LPS for 6h ) whole cell lysate 10 μg (Input).
      Lane 2: ab190831 IP in RAW 264.7 (treated with 1μg/ml LPS for 6h) whole cell lysate. 
      Lane 3: : Rabbit monoclonal IgG (ab172730) instead of ab190831 in RAW 264.7 (treated with 1μg/ml LPS for 6h) whole cell lysate. 

      Blocking and dilution buffer and concentration: 5% NFDM/TBST.
      Exposure time: 1 second.

      The molecular weight observed is consistent with what has been described in the literature (PMID: 19620301, PMID: 12121660).

    References

    ab190831 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab190831.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up